Kazia Advances Paxalisib in Rare Seizure Disorders
Sydney, Australia, September 21, 2026 Kazia Therapeutics Limited has announced that its development partner Sovargen Co., Ltd. has dosed...
Kazia Therapeutics
Advertisement
Kazia Expands Paxalisib Trial Into HR+ Breast Cancer
Sydney, Australia, September 1, 2026 Kazia Therapeutics has announced plans to expand its ongoing paxalisib clinical trial into hormone...
Paxalisib Boosts Anti-Tumor Immunity in Advanced Breast Cancer
SYDNEY, Dec. 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) unveiled compelling clinical and translational data highlighting the ability...
FDA Grants Priority Review to AstraZeneca’s Baxdrostat NDA for Hard-to-Control Hypertension
Cambridge, UK & Wilmington, Delaware, December 2025 — AstraZeneca has announced that the U.S. Food and Drug Administration has...
Formosa Licenses Ophthalmic Clobetasol Suspension to Rxilient for Asia Commercialization
Taipei, Taiwan, December 2025 — Formosa Pharmaceuticals has announced a licensing agreement with Rxilient Biotech to commercialize clobetasol propionate...
Advertisements
Kazia Therapeutics Secures $50M Private Placement to Strengthen Pipeline Funding
Sydney, Australia, December 3, 2025 — Kazia Therapeutics has announced the pricing of a US $50 million private placement...
Advertisement
